Skip Navigation


European Heart Journal Advance Access originally published online on September 29, 2005
European Heart Journal 2005 26(21):2218-2219; doi:10.1093/eurheartj/ehi464
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
26/21/2218    most recent
ehi464v2
ehi464v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Dickstein, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dickstein, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

C-reactive protein in ischaemic cardiomyopathy: assessing vascular risk in heart failure

Kenneth Dickstein*

Division of Cardiology, University of Bergen, Stavanger University Hospital, Norway

* Corresponding author. Tel: +47 51 51 8000; fax: +47 51 51 9921. E-mail address: trout@online.no

This editorial refers to ‘High-sensitivity C-reactive protein: potential adjunct for risk stratification in patients with stable congestive heart failure’{dagger} by N. Lamblin et al., on page 2245

The first 10% of the full text of this article appears below.

The paper ‘High-sensitivity C-reactive protein: potential adjunct for risk stratification in patients with stable congestive heart failure’ by Lamblin et al.1 clearly demonstrates the prognostic value of this measurement in patients with well-compensated heart failure due to ischaemic cardiomyopathy. Importantly, C-reactive protein did not provide significant prognostic information in the population with dilated cardiomyopathy without evidence of coronary artery disease.

The study included 545 patients referred for evaluation of symptomatic heart failure. During a median follow-up of 972 days, a C-reactive protein >3 mg/L was found to be highly predictive of cardiovascular mortality in patients with ischaemic etiology (113 events, 80% 3-year survival) with a hazard ratio of 2.17 (. . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

High-sensitivity C-reactive protein: potential adjunct for risk stratification in patients with stable congestive heart failure
Nicolas Lamblin, Frédéric Mouquet, Bernadette Hennache, Joël Dagorn, Sophie Susen, Christophe Bauters, and Pascal de Groote
EHJ 2005 26: 2245-2250. [Abstract] [Full Text]